SUMMARY
Alzheimer's disease (AD) is a genetically heterogeneous disorder characterized by early hippocampal atrophy and cerebral amyloid-b (Ab) peptide deposition. Using TissueInfo to screen for genes preferentially expressed in the hippocampus and located in AD linkage regions, we identified a gene on 10q24.33 that we call CALHM1. We show that CALHM1 encodes a multipass transmembrane glycoprotein that controls cytosolic Ca 2+ concentrations and Ab levels. CALHM1 homomultimerizes, shares strong sequence similarities with the selectivity filter of the NMDA receptor, and generates a large Ca 2+ conductance across the plasma membrane. Importantly, we determined that the CALHM1 P86L polymorphism (rs2986017) is significantly associated with AD in independent case-control studies of 3404 participants (allele-specific OR = 1.44, p = 2 3 10 À10 ). We further found that the P86L polymorphism increases Ab levels by interfering with CALHM1-mediated Ca 2+ permeability. We propose that CALHM1 encodes an essential component of a previously uncharacterized cerebral Ca 2+ channel that controls Ab levels and susceptibility to late-onset AD.
INTRODUCTION
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by a massive loss of neurons in several brain regions and by the presence of cerebral senile plaques comprised of aggregated amyloid-b (Ab) peptides (Mattson, 2004; Selkoe, 2001) . The first atrophy observed in the AD brain occurs in the medial temporal lobe, which includes the hippocampus, and is the result of a massive synaptic degeneration and neuronal death (Braak and Braak, 1991; de Leon et al., 2007) . Two major Ab species are found, Ab40 and Ab42; both are produced from the sequential endoproteolysis of the amyloid precursor protein (APP) by BACE1/b-secretase and by presenilin (PS)/g-secretase complexes. APP can also undergo a nonamyloidogenic proteolysis by a-secretase, which cleaves APP within the Ab sequence and thereby precludes Ab generation (Marambaud and Robakis, 2005; Wilquet and De Strooper, 2004) .
The etiology of the disease is complex because of its strong genetic heterogeneity. Rare autosomal-dominant mutations in the genes encoding APP, PS1, and PS2 cause early-onset AD, whereas complex interactions among different genetic variants and environmental factors are believed to modulate the risk for the vast majority of late-onset AD (LOAD) cases (Kennedy et al., 2003; Lambert and Amouyel, 2007; Pastor and Goate, 2004) . To date, the only susceptibility gene unambiguously demonstrated worldwide is the 34 allele of APOE on chromosome 19 (Strittmatter et al., 1993) . However, epidemiological studies indicate that the presence of the APOE 34 allele cannot explain the overall heritability of AD, implying that a significant proportion of LOAD cases is attributable to additional genetic risk factors (Lambert and Amouyel, 2007; Pastor and Goate, 2004) . Supporting this observation, concordant evidence of linkage to LOAD has been observed in different chromosomal regions, including on chromosome 10, where a strong and consensual susceptibility locus is present (Bertram et al., 2000; Blacker et al., 2003; Ertekin-Taner et al., 2000; Farrer et al., 2003; Kehoe et al., 1999; Myers et al., 2000) . However, despite intensive research efforts to characterize the genetic factor(s) located within the chromosome 10 region, no gene has been conclusively linked to LOAD risk (Bertram et al., 2006; Grupe et al., 2006; Kuwano et al., 2006; Minster et al., 2006) .
A number of neurodegenerative disorders are caused by mutations in genes expressed principally in the central nervous system. This is the case for the brain proteins tau and a-synuclein, which are linked to autosomal-dominant forms of frontotemporal dementia and Parkinson's disease, respectively. Here, we postulated that susceptibility to LOAD could come from genes predominantly expressed in affected brain regions, such as the hippocampus. We used TissueInfo (Skrabanek and Campagne, 2001) and the Alzgene database (Bertram et al., 2007) to screen for genes predominantly expressed in the hippocampus and located in linkage regions for LOAD, and identified CALHM1, a gene of unknown function, located on chromosome 10 at 1.6 Mb of the LOAD marker D10S1671 (Bertram et al., 2000) . We found that CALHM1 homomultimerizes, controls cytosolic Ca 2+ concentrations, and shares similarities with the predicted selectivity filter of the N-methyl-D-aspartate receptor (NMDAR). Voltage-clamp analyses further revealed that CALHM1 generates Ca
2+
-selective cation currents at the plasma membrane. Importantly, we determined that the frequency of the rare allele of the nonsynonymous single-nucleotide polymorphism (SNP) rs2986017 in CALHM1, which results in a proline-to-leucine substitution at codon 86 (P86L), is significantly increased in AD cases in five independent cohorts. Further investigation demonstrated the functional significance of the rs2986017 SNP by showing that the P86L mutation promotes Ab accumulation via a loss of CALHM1 control on Ca 2+ permeability and cytosolic Ca 2+ levels. Here, we propose that CALHM1 is a component of a previously uncharacterized cerebral Ca 2+ channel family involved in Ab metabolism and that CALHM1 variants may influence the risk for LOAD.
RESULTS

Gene Discovery
We screened the human genome with TissueInfo to annotate human transcripts with tissue expression levels derived from the expressed sequence tag database (dbEST) (Campagne and Skrabanek, 2006; Skrabanek and Campagne, 2001 ). Out of 33,249 human transcripts, the TissueInfo screen identified 30 transcripts, corresponding to 12 genes, with expression restricted to the hippocampus (Table 1) . These transcripts matched either one or two ESTs sequenced from the hippocampus. Among these genes, one of unknown function, previously annotated as FAM26C, matched two hippocampal ESTs and mapped to the AD locus on 10q24.33 (Table 1) . This gene, hereafter referred to as calcium homeostasis modulator 1 (CALHM1), encodes an open reading frame (ORF) of 346 amino acids and is predicted to contain four hydrophobic domains (HDs; TMHMM prediction) and two N-glycosylation motifs (NetNGlyc 1.0 prediction) ( Figure 1A ). No significant amino acid sequence homology to other functionally characterized proteins was found. Sequence database searches identified five human homologs of CALHM1 (collectively identified as the FAM26 gene family). Two homologs of human CALHM1 with broader tissue expression profiles (see the Supplemental Data available online) are clustered next to CALHM1 in 10q24.33 and are designated CALHM2 (26% protein sequence identity, previously annotated as FAM26B) and CALHM3 (39% identity, FAM26A) ( Figure 1A ). CALHM1 is conserved across at least 20 species, including mouse and C. elegans ( Figures 1A and 1B) .
CALHM1 Characterization
Using RT-PCR, we analyzed human CALHM1 expression in 20 tissues and six brain regions. The expression of CALHM1 was highest in the total adult brain and in all brain regions tested. CALHM1 expression was noticeably lower in all other tissues, including fetal brain ( Figure 2A ). qRT-PCR revealed endogenous CALHM1 expression in retinoic acid-differentiated SH-SY5Y cells ( Figure S1A ), suggesting that CALHM1 is a protein of neuronal origin. Immunofluorescence staining in transiently transfected cells revealed that CALHM1 strongly localized to the endoplasmic reticulum (ER), where it colocalized with the ER resident protein GRP78 ( Figure 2B , left and middle panels). However, some cells revealed immunoreactivity for CALHM1 at the cell surface, suggesting that a pool of CALHM1 was localized at or near the plasma membrane ( Figure 2B , right panel, arrows). Western blotting (WB) analyses revealed the presence of two immunoreactive bands in CALHM1-transfected cells ( Figure 2C , lanes 1 and 2). Because human CALHM1 is predicted to be N-glycosylated at asparagine residues N74 and N140 (see Figure 1A , asterisks), we asked whether these bands might represent different N-glycosylated forms of the protein. Treatment of CALHM1-transfected cell lysates with N-glycosidase F, which cleaves all types of asparagine-bound N-glycans, completely eliminated the appearance of the higher molecular weight band and resulted in the accumulation of the lower band, which we conclude corresponds to the unmodified core protein ( Figure 2C , lanes 2 and 4). CALHM1 was partially resistant to endoglycosidase H-mediated deglycosylation ( Figure 2C , lanes 2 and 3), indicating that CALHM1 can reach the medial Golgi compartment and the cell surface, where proteins are terminally glycosylated and acquire resistance to endoglycosidase H. Plasma membrane expression of CALHM1 was also investigated by cell surface biotinylation. Figure 2D illustrates that a pool of CALHM1, enriched in glycosylated forms of the protein, was biotinylated and thus was present at the plasma membrane. We further determined that substitution of the N140 residue to alanine (N140A) completely prevented CALHM1 glycosylation, whereas N74A substitution had no effect ( Figure 2C , lanes 5-7). Thus, CALHM1 is a multipass transmembrane protein, N-glycosylated at the residue N140, predominantly expressed in the adult brain, and localized to the ER and plasma membranes. These data further indicate that the HD3-HD4 loop, which contains the N140 residue, is oriented toward the luminal side when CALHM1 is in the ER membrane and toward the extracellular space when CALHM1 reaches the plasma membrane.
CALHM1 Controls Cytosolic Ca 2+ Levels
The predicted membrane topology of CALHM1 suggests the presence of one re-entrant hydrophobic loop that does not cross the membrane bilayer and three membrane-spanning segments (TMHMM prediction). In the absence of significant homology to other characterized proteins, we postulated from the predicted topology that CALHM1 could function as an ion channel component. This is in part based on a suggestive similarity with the topology of ionotropic glutamate receptors, which also contain three transmembrane segments and a re-entrant loop that forms the lining of the ion channel pore region (Wollmuth and Sobolevsky, 2004 ] i (from 105 ± 5 nM to 110 ± 6 nM; Figure S2 ). Because massive Ca 2+ influx can be cytotoxic, we evaluated the viability of cells expressing CALHM1. Figure S3 illustrates represent another critical mechanism of Ca 2+ influx during membrane depolarization (Berridge et al., 2003) . Inhibition of SOCE by the use of 2-APB did not prevent CALHM1 from affecting [Ca 2+ ] i ( Figure 3C ). Similarly, selective blockage of the different subtypes of VGCCs with SNX-482 (R type VGCC inhibitor), mibefradil (T type), nifedipine (L type), or u-conotoxin MVIIC (N, P, Q types) did not block the rise of [Ca 2+ ] i induced by CALHM1 expression ( Figures 3D and 3E ). Because cytosolic Ca 2+ can be released from intracellular stores via activation of the inositol 1,4,5-triphosphate receptors (InsP 3 Rs) or the ryanodine receptors (RyRs) at the ER membrane (Berridge et al., 2003) , we next asked whether CALHM1 expression promotes InsP 3 R or RyR activation. The InsP 3 R inhibitor xestospongin C and the RyR inhibitor dantrolene were found to have no effect on the CALHM1-driven [Ca 2+ ] i increase ( Figure 3F ), indicating that ER Ca 2+ release via InsP 3 Rs or RyRs did not account for the effect of CALHM1 on cytosolic Ca 2+ levels. Because presenilins were recently proposed to form ER calcium leak channels (Tu et al., 2006) , we also investigated whether CALHM1 requires the presence of PS1 or PS2 to control cytosolic Ca 2+ levels. We found that CALHM1 expression caused similar increases in [Ca 2+ ] i in WT fibroblasts and in fibroblasts deficient for both PS1 and PS2 ( Figure S4 by CALHM1 without causing changes in CALHM1 expression ( Figure 3I ). Because Ni 2+ does not penetrate the cells (Shibuya and Douglas, 1992) , these results suggest that the two inorganic Ca 2+ channel blockers acted at the plasma membrane to block 
CALHM1 Has Ion Channel Properties
Because many channels multimerize to form an ion pore, and because monomeric CALHM1 cannot create a functional pore with three transmembrane segments, we asked whether CALHM1 could form multimers. WB analyses of CALHM1-transfected cells under nonreducing conditions revealed the presence of immunoreactive bands with molecular weights compatible with dimers and tetramers of CALHM1 ( Figure 4A ). To test the possibility that CALHM1 self-associates, we coexpressed in cells two different tagged versions of the protein and used coimmunoprecipitation experiments to determine whether the two versions of CALHM1 form a complex. We found that immunoprecipitation of Myc-tagged CALHM1 coprecipitated V5-tagged CALHM1 ( Figure 4B ), indicating that CALHM1 homomultimerized to form dimeric and possibly tetrameric structures. Ionotropic glutamate receptors are ion-conducting membrane proteins with specific ion-selectivity properties (Gouaux and Mackinnon, 2005) . Recent advances in the structural analysis of ion channels have determined that the ion selectivity of some ion channels is controlled by a short amino acid sequence called the selectivity filter, which forms a narrow constriction in the pore across the membrane bilayer (Gouaux and Mackinnon, 2005) . The predicted selectivity filter of ionotropic glutamate receptors is located in a re-entrant loop called M2 and is critical for Ca 2+ permeability (Dingledine et al., 1999; Wollmuth and Sobolevsky, 2004) . By manual inspection, we screened ionotropic glutamate receptor subunit sequences for similarities with CALHM1 and found a short sequence in C terminus of CALHM1 HD2 that aligns with the predicted ion-selectivity filter of NMDAR NR2 subunits ( Figure 4C ). Previous studies have determined that the asparagine (N) residue in the so-called Q/R/N site of NMDAR NR2 subunits is critical for ion selectivity and permeation (see Figure 4C , asterisk) (Wollmuth and Sobolevsky, 2004) . By sequence comparison, we identified a highly conserved N72 residue in human CALHM1 that aligns with the Q/R/N site at the C terminus end of the second hydrophobic domain of both CALHM1 and NMDAR ( Figure 4C, asterisk) . Importantly, we found that mutagenesis of the N72 residue to glycine (N72G) resulted in a significant inhibition of the effect of CALHM1 on [Ca 2+ ] i ( Figures 4D and 4E ).
Two-electrode voltage clamping of Xenopus oocytes was employed so that the effects of CALHM1 expression on plasma membrane conductance could be determined. Oocytes were injected with either water or CALHM1 cRNA, and conductance was recorded 24-72 hr later in a normal Na + -containing bath. In water-injected oocytes, the resting membrane potential V m was À38mV ± 1mV (n = 74), and the membrane conductance, measured as the slope conductance around the reversal potential V rev , was 1.5 ± 0.2 mS (n = 7). In contrast, the V m in CALHM1-expressing oocytes was depolarized to À16mV ± 0.3mV (n = 96; p < 0. 0001), and membrane conductance was enhanced to 422 ± 78 mS (n = 12) (p < 0.005). The current-voltage (I-V) relation was outwardly rectifying (slope conductances of 372 ± 110 and 670 ± 131 mS at À55mV and +55mV, respectively) ( Figure 4F ). Depolarization of the resting V m suggested that the CALHM1-enhanced conductance was contributed by a Na + permeability. Isosmotic replacement of bath Na + with NMDG hyperpolarized V m by 7mV ± 0.8mV ( Figure 4F ; n = 12; p < 0.0001). These results demonstrate that expression of CALHM1 conferred a constitutive Na + conductance in Xenopus oocyte plasma membrane. Expression of CALHM1 in CHO cells also generated an outwardly rectifying current in whole-cell recordings with Cs + in the pipette (cytoplasmic) and Na + in the bath ( Figure 4G ). The current reversed $0mV, indicating that the relative permeabilities of Cs + and Na + were similar (P Na : P Cs = 0.8). The current was not observed in either untransfected or EGFP-transfected cells ( Figure 4G , control), and it was eliminated when the monovalent cations in the bath and pipette solutions were replaced with NMDG ( Figure 4H ), indicating that the current was carried by Cs + and Na + . The CALHM1-induced slope conductance measured around the V rev was 360 ± 60 pS/pF (n = 42), compared with 74 ± 17 pS/pF (n = 11) in control cells. Gd 3+ (100 mM) nearly completely inhibited the CALHM1-induced current ( Figure 4G ). With bath Na + replaced by NMDG and 20 mM Ca
2+
, an outwardly rectifying, Gd 3+ -sensitive current was observed in the CALHM1-expressing cells that reversed at +8.3mV ± 2.9mV (n = 7), indicating P Ca : P Cs = 5 ( Figure 4H ). Thus, expression of CALHM1 conferred a constitutive Ca 2+ -selective cation current in CHO cell plasma membrane.
In summary, our studies show that a region of CALHM1 shares sequence similarities with the selectivity filter of NMDAR and that the N72 residue is a key determinant in the control of cytosolic Ca 2+ levels by CALHM1. Furthermore, electrophysiological analyses in CALHM1-expressing Xenopus oocytes and CHO cells demonstrated that CALHM1 induced a previously uncharacterized plasma membrane Ca 2+ -selective cation current. Together with the observation that the effect of CALHM1 had properties that did not overlap those of known Ca 2+ channels, these results suggest that CALHM1 may be a previously uncharacterized pore-forming ion channel.
CALHM1 Controls APP Processing
Because cytosolic Ca 2+ is critical for the regulation of APP processing (LaFerla, 2002), we asked whether CALHM1 expression influences Ab levels. Figure 5A shows that, under resting conditions with physiological concentrations of extracellular Ca 2+ , CALHM1 expression in APP-transfected mouse neuroblastoma N2a cells had no noticeable effect on extracellular Ab levels (panel a, lanes 1-4) . Under Ca 2+ add-back conditions, however, expression of CALHM1 strongly and significantly decreased total extracellular Ab accumulation ( Figure 5A, panel b, lanes 1-4) , including Ab1-40 and Ab1-42 ( Figure 5B) . Importantly, the decrease in Ab levels triggered by CALHM1 expression was accompanied by an elevation of sAPPa levels, whereas cellular fulllength APP remained unchanged ( Figure 5A , panels c and d, lanes 1-4). The effect of endogenous CALHM1 on APP processing was studied in differentiated neuroblastoma cells. We found that neuronal differentiation with retinoic acid, a condition which we showed induces endogenous CALHM1 expression in SH-SY5Y cells (Figure S1A ), resulted in a robust decrease of extracellular Ab levels ( Figures S1B and S1C) . Although the inhibitory effect of neuronal differentiation on Ab accumulation was observed both in the presence and absence of Ca 2+ add-back conditions, it was significantly potentiated upon Ca 2+ add-back conditions after 6 days of differentiation ( Figure S1C ), suggesting that Ab levels were regulated by Ca 2+ influx in these conditions. Strikingly, inhibition of endogenous CALHM1 expression by RNA interference led to a significant increase of Ab levels in differentiated cells after Ca 2+ add back ( Figures 5C-5E ). These data demonstrate that endogenous CALHM1 contributes to the inhibitory effect of neuronal differentiation on Ab accumulation. Thus, CALHM1 expression controls APP processing by interfering with extracellular Ab accumulation and by promoting sAPPa accumulation. The effects of CALHM1 on the regulation of Ab and sAPPa levels are in line with its effect on [Ca 2+ ] i , indicating that CALHM1 controls APP proteolysis in a Ca 2+ -dependent manner. 
(G) and NiCl 2 (H). Traces in (C)-(H) illustrate representative measurements of two to three independent experiments. (I) WB with anti-Myc (upper panels) and anti-actin (lower panels) antibodies of protein extracts obtained from cells treated as in (G) and (H).
The CALHM1 P86L Polymorphism Is Associated with LOAD and Affects Plasma Membrane Ca 2+ Permeability, Cytosolic Ca 2+ Concentration, and Ab Levels
Because CALHM1 maps to a chromosomal region associated with susceptibility for LOAD, we tested whether CALHM1 SNPs could be associated with the risk of developing the disease. Two nonsynonymous SNPs were reported in databases, rs2986017 (+394 C/T; P86L) and rs17853566 (+927 C/A; H264N). We sequenced the entire CALHM1 ORF using genomic DNA from 69 individuals, including 46 autopsy-confirmed AD cases and 23 age-matched normal controls. The rs17853566 SNP was not observed in this group. However, we confirmed the presence of the rs2986017 SNP with a potential overrepresentation of the T allele in AD subjects (AD = 36%, controls = 22%; Total secreted Ab and sAPPa and cellular APP and Myc-CALHM1 were analyzed by WB (A). Secreted Ab1-40 and Ab1-42 were analyzed by ELISA in the presence of Ca 2+ add-back conditions (n = 12; Student's t test) (B).
(C-E) APP 695 -SH-SY5Y cells differentiated for 15 days with retinoic acid were treated for 3 days with Accell siRNAs directed against human CALHM1. Medium was then changed and cells were incubated for 90 min in the absence or presence of Ca 2+ add-back conditions. Total secreted Ab and cellular APP and actin were analyzed by WB (C). Total secreted Ab1-x was quantified by ELISA (n = 3; Student's t test) (D). CALHM1 mRNA levels were assayed by real-time qRT-PCR analysis. Histogram illustrates the mean relative CALHM1 expression ± SD (control, n = 4; CALHM1 siRNA, n = 3) (E). Table 2 and Figure 5F ; USA screening sample). We next assessed the impact of rs2986017 on the risk of developing AD in four other independent case-control populations (2043 AD cases and 1361 controls combined, Table 2 ). The T allele distribution was increased in AD cases as compared to controls in all the studies, with odds ratios (ORs) ranging from 1.29 to 1.99 (OR = 1.44, p = 2 3 10 À10 in the combined population; Figure 5F ). This association was highly homogeneous among the different case-control studies (test for heterogeneity, p = 0.59, I 2 = 0%). We also observed that the T allele frequency in autopsy-confirmed AD cases was similar to that observed in probable AD case populations (Table 2). In the combined population, the CT or TT genotypes were both associated with an increased risk of AD development (respectively, OR CT versus CC ranging from 1.18 to 1.64, OR = 1.37, p = 3 3 10 À5 in the combined population and OR TT versus CC ranging from 1.44 to 4.02, OR = 2.03, p = 2 3 10 À7 in the combined population; Table 2 ). All these observations were independent of the APOE status (Table 2 and p for interaction = 0.26).
It is important to note that the rs2986017 distribution was in Hardy-Weinberg equilibrium in the different control populations but not in the combined one (c2 = 6.35, df = 1, p = 0.01; Table 2 ). Since we mainly used direct sequencing for genotyping, the potential for technical biases is limited. It is therefore possible that the slight deviation from the expected genotype distribution might be linked to a loss of heterozygosity by copy-number variations (CNVs) in the CALHM1 gene. We found no evidence of common CNV encompassing the rs2986017 locus (see the Supplemental Data). However, we cannot exclude that the deletion of a short-sized segment around rs2986017 disrupts the Hardy-Weinberg equilibrium for this marker.
Further evidence of the influence of the CALHM1 gene on the risk of developing AD comes from the observation that, in the France I population, patients bearing the TT genotype had an earlier age at onset compared with the CT and CC carriers (66.8 ± 8.5 versus 68.7 ± 7.7 years; p = 0.05). We observed the same trend in the autopsied UK brain cohort (60.5 ± 6.4 versus 65.2 ± 10.3 years; p = 0.12) and in the Italian population (70.6 ± 9.7 versus 74.3 ± 8.5 years; p = 0.10), but not in the France II population (64.4 ± 8.8 versus 64.6 ± 9.8 years; p = nonsignificant [ns]). When the AD case populations were combined, the TT genotype was still associated with an earlier age at onset compared with the CT and CC carriers (65.7 ± 8.8 versus 67.1 ± 9.3 years; p = 0.03 adjusted for gender, APOE status, and center).
In order to gain insight into the relevance of the rs2986017 SNP to the disease, we first investigated the effect of the corresponding P86L substitution on Ca 2+ permeability and [Ca 2+ ] i . Similar to WT-CALHM1, P86L-CALHM1 expressed in CHO cells generated a Gd 3+ -sensitive outwardly rectifying cation current that reversed near 0mV with Cs + and Na + in the pipette and bath solutions, respectively (data not shown). However, with bath Na + replaced by NMDG and 20 mM Ca 2+ , the current reversed at À8.9mV ± 3.6mV ( Figure 5G ; n = 6), $17mV hyperpolarized compared with the currents recorded in WT-CALHM1-expressing cells, resulting in a reduced Ca 2+ selectivity, P Ca : P Cs = 2 (Figure 5G) . Thus, the P86L polymorphism significantly reduced CALHM1-induced Ca 2+ permeability. In addition, we observed that the P86L mutation caused a significant inhibition of the effect of CALHM1 on [Ca 2+ ] i ( Figures 5H and 5I ), reducing its values at the peak after Ca 2+ add back, from 264 ± 48 nM to 192 ± 34 nM ( Figure S2 ). We then asked whether the P86L polymorphism affects the control of APP processing by CALHM1. Whereas expression of WT-CALHM1 was found to stimulate sAPPa accumulation and to repress total Ab secretion, the ability of the P86L-mutated CALHM1 to control APP processing was greatly impaired ( Figure 5A , panels b and c), while WTand P86L-CALHM1 were expressed at comparable levels ( Figure 5A , panel e). Consequently, compared to WT-CALHM1, P86L-CALHM1 reduced sAPPa accumulation ( Figure 5A , panel c, lanes 3-6) and led to a significant elevation of total secreted Ab levels ( Figure 5A, panel b, lanes 3-6) , including Ab1-40 and Ab1-42 ( Figure 5B ), indicating that the P86L mutation significantly impaired the effect of CALHM1 on the extracellular accumulation of sAPPa and Ab. Collectively, these data show that the P86L polymorphism causes a partial loss of CALHM1 function by interfering with its control of Ca 2+ permeability, cytosolic Ca 2+ concentration, APP metabolism, and Ab levels.
DISCUSSION
Using a bioinformatics strategy to screen for genes predominantly expressed in the hippocampus and located in linkage regions for LOAD, we identified CALHM1 on chromosome 10 (Table 1). CALHM1 was found to encode an integral membrane glycoprotein with key characteristics of a Ca 2+ channel.
CALHM1 controls cytosolic Ca 2+ levels, homomultimerizes, and shares important sequence similarities with the predicted selectivity filter of NMDAR (Figures 3 and 4) . Significantly, we have also demonstrated that CALHM1 contains a functionally important N residue at position 72 that aligns with the Q/R/N site of the NMDAR selectivity filter (Figure 4) . Thus, NMDAR and CALHM1 share important structural similarities at the sequence level in a region that was previously described as a critical determinant of Ca 2+ selectivity and permeability in glutamate receptor ion channels (Wollmuth and Sobolevsky, 2004) . The potential role of CALHM1 in ion permeability was further investigated by voltage clamping with two different cell models. This approach demonstrated that expression of CALHM1 generates (F) Five independent case-control studies were analyzed to assess the association of rs2986017 with AD risk. The allelic OR (T versus C) was estimated in each population and in the combined one. 1 Test for heterogeneity: X 2 = 2.84, df = 4, p = 0.59; Test for overall effect: Z = 6.06, p = 2 3 10 À9 (Mantel-Haentzel method, fixed OR = 1.42 [1.27-1.59]).
(G) Whole-cell currents in CHO cells expressing WT (blue trace; C m = 13.2 pF) or P86L-CALHM1 (green trace; C m = 22.9 pF) in the same bi-ionic conditions as in Figure 4H . P86L-CALHM1-expressing cells remained sensitive to block by 100 mM Gd 3+ (red trace), but the reversal potential was shifted to more hyperpolarized voltages (V rev = À8.9mV ± 3.6mV ; n = 6), indicating a reduced Ca 2+ permeability (P Ca : P Cs = 2) compared with that of WT-CALHM1. a previously uncharacterized constitutive Ca 2+ selective cation current at the plasma membrane. Additional studies that will examine the topology of CALHM1 and more precisely the organization of the region containing the critical N72 residue will help us to clearly identify the role of CALHM1 in ion permeation.
In the present report, we have provided compelling evidence that the rs2986017 SNP in CALHM1, which results in the P86L substitution, is associated with both an increased risk for LOAD and a significant dysregulation of Ca 2+ homeostasis and APP metabolism (Table 2 and Figure 5 ). Specifically, we have shown that the P86L polymorphism impairs plasma membrane Ca 2+ permeability, reduces cytosolic Ca 2+ levels, affects sAPPa production, and concomitantly derepresses the effect of CALHM1 on Ab accumulation. A large body of literature supports the notion that a deranged intracellular Ca 2+ signaling occurs in AD and may be involved in the deregulation of APP processing and neurodegeneration (Khachaturian, 1989; LaFerla, 2002) .
APP metabolism involves a complex series of events, and the direct influence of Ca 2+ signaling on this process is still poorly understood (LaFerla, 2002) . The present work provides strong support for the Ca 2+ hypothesis of AD and is also an important step toward understanding the potential pathological cross talk between Ca 2+ signaling disturbances and pathways of Ab accumulation. Moreover, the identification of CALHM1 as a key modulator of Ca 2+ homeostasis will allow us to further dissect the precise mechanism by which cytosolic Ca 2+ modulates APP metabolism.
Screening the human genome for genes predominantly expressed in the hippocampus successfully prioritized CALHM1 among the many genes found in LOAD loci and thus demonstrates the utility of tissue expression profiling in the identification of candidate genes for LOAD. Candidate genes located in LOAD regions are often considered on the basis of their potential implication in known AD biology (e.g., IDE). The strategy used in this Campagne, 2007, Soc. Neurosci., abstract.) .
In summary, we propose that CALHM1 is a pore component of a previously uncharacterized cerebral ion channel family and that variants in the CALHM genes may constitute robust risk factors for LOAD. These results not only provide important new insights into the pathophysiology of Ca 2+ homeostasis and APP metabolism in the central nervous system but also represent a strong genetic evidence of a channelopathy contribution to AD etiology. Finally, given its cell-surface ion channel properties and its restricted expression, our work further establishes CALHM1 as a potentially important molecular target for an anti-amyloid therapy in AD.
EXPERIMENTAL PROCEDURES Bioinformatics Analyses Tissue Expression Profiles
We generated whole-genome human tissue expression profiles by using TissueInfo (http://icb.med.cornell.edu/crt/tissueinfo/index.xml), information in Ensembl (human build NCBI35), and dbEST. TissueInfo profiling was done as previously described (Campagne and Skrabanek, 2006; Skrabanek and Campagne, 2001 ). Whole-genome profiles were filtered with InsightfulMiner 7.0 (Insightful) to extract the subset of transcripts annotated by TissueInfo as ''specific to hippocampus.'' LOAD Locus Screen The 30 transcripts predicted to be specific to the hippocampus by TissueInfo were annotated with their genomic location with EnsMart/Biomart (Kasprzyk et al., 2004) and data from Ensembl. Chromosome numbers and FISH band locations were used to identify those transcripts that matched a locus of susceptibility to AD, as documented in AlzGene (Bertram et al., 2007) .
CALHM1 Subcloning and Mutagenesis
Human CALHM1 cDNA was obtained from ATCC. The ORF was subcloned in frame with a carboxy-terminal Myc-His or V5 tag into the pcDNA3.1 vector for expression experiments. P86L, N72G, N74A, and N140A mutations were introduced with the QuikChange II site-directed mutagenesis kit (Stratagene) and confirmed by sequencing. WB and ELISA For APP processing analysis, APP-transfected cells were challenged with Ca 2+ add-back conditions, as described above. Conditioned medium and cells were harvested after the indicated times of incubation at 37 C in a humidified 5% CO 2 incubator. Secreted Ab WB was performed as previously described . WB of sAPPa and APP was performed with 6E10 (Signet) and LN27 (Zymed) antibodies, respectively. For ELISA, secreted Ab1-40, Ab1-42, and Ab1-x levels were quantified per the manufacturer's recommendations (IBL-America). ELISA plates were read on a Tecan GENios Pro reader at 450 nm.
CALHM1
Sequencing CALHM1 ORF was resequenced with genomic DNA preparations obtained from 23 control individuals (age at study = 71.9 ± 16.0 years, 43% male) and 46 autopsy-confirmed AD patients (age at study = 77.8 ± 8.1 years, 55% male). Subjects and genomic DNA preparations were described elsewhere (Conrad et al., 2002) . ORFs were amplified by PCR with primers described in the Supplemental Data, and PCR products were sequenced by GeneWiz.
SNP Analyses
Populations See the Supplemental Data. Genotyping In the France I population, the P86L genotype was determined by genomic DNA amplification. The genotyping of 176 individuals was checked by direct sequencing. Only two discrepancies were observed between CC and CT genotypes. In the UK, France II, and Italy populations, the P86L genotype was entirely determined by direct sequencing. See Supplemental Data for experimental details.
Statistical Analyses
Univariate analysis was performed with Pearson's c 2 test. The review manager software release 5.0 (http://www.cc-ims.net/RevMan/) was used to test for heterogeneity between the different case-control studies and to estimate the overall effect (Mantel-Haentzel fixed odds ratio; Figure 5F ). For multivariate analysis, SAS software release 8.02 was used (SAS Institute, Cary, NC), and homogeneity between populations was tested with Breslow-day computation (Breslow et al., 1978) . The association of the P86L polymorphism with the risk of developing AD was assessed by a multiple logistic regression model adjusted for age, gender, APOE status, and center. Interactions between age, gender, or APOE and the P86L polymorphism were tested by logistic regression. No significant statistical interactions were detected. Finally, the potential impact of the P86L polymorphism on age at onset was assessed with a general linear model adjusted for gender, APOE status, and center.
Electrophysiology
Xenopus oocyte plasma membrane conductance was recorded 24-72 hr after cRNA injection. Single oocytes were placed in a 1 ml chamber containing LCa96 solution. In some studies, Na + was replaced with NMDG. Conventional two-electrode voltage clamp was performed. Pulse+PulseFit software (HEKA Elektronik) was used to ramp the applied transmembrane potential (V m ) at 10 s intervals from À80mV to 80mV at 16mV/s and to acquire data. V m was clamped at the resting membrane potential between voltage ramps. Transmembrane current (I) and V m were digitized at 200 Hz and recorded directly to hard disk. So that the reversal potential V rev could be determined, a fifthorder polynomial was fitted to the raw I-V m data acquired during each voltage ramp, with macros developed in Igor Pro software (WaveMetrics). Whole-cell recordings of CHO cells were performed with 2-5 MU pipettes with an Axopatch 200-B amplifier (Axon Instr.). Current-voltage (I-V) relationships were acquired in response to voltage ramps (±100mV, 2 s duration). The recording chamber was continuously perfused with bath solution (2 ml/min). See the Supplemental Data for experimental details. Data analyzed with macros developed in Igor Pro were corrected for leakage currents (determined from a linear fit of the currents recorded at À80mV to À100mV in the presence of 100 mM GdCl 3 extrapolated over the entire ramping voltage domain) and for measured junction potentials. I-V curves presented in the figures have not been corrected for leakage current. Calculated values are given as means ± SEM.
ACCESSION NUMBERS
Human CALHM1 (previously annotated FAM26C) has Ensembl release 43 accession code ENSG00000185933 (Uniprot Q8IU99). CALHM3 has accession code ENSG00000183128, and CALHM2 has accession code ENSG00000138172. See the Supplemental Data for additional accession numbers.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Results, Supplemental Experimental Procedures, Supplemental References, and four figures and can be found with this article online at http://www.cell.com/cgi/content/full/133/7/1149/ DC1/.
